EDSA
Edesa Biotech, Inc.Healthcare · $26M market cap
Verdict
We can't put a fair value on EDSA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow EDSA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 28, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about EDSA
Are insiders buying EDSA?
Since Oct 28, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar).
How can I check EDSA's value myself?
Use the free Sticker Price calculator, already filled with EDSA's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Edesa Biotech, Inc.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 29, 2026. How the Payback Price works